21 results on '"Maria G. Tsokos"'
Search Results
2. The PP2A regulatory subunit PPP2R2A controls NAD+ biosynthesis to regulate T cell subset differentiation in systemic autoimmunity
- Author
-
Wenliang Pan, Maria G. Tsokos, Marc Scherlinger, Wei Li, and George C. Tsokos
- Subjects
CP: Immunology ,CP: Metabolism ,Biology (General) ,QH301-705.5 - Abstract
Summary: The protein phosphatase 2A (PP2A) regulatory subunit PPP2R2A is involved in the regulation of immune response. We report that lupus-prone mice with T cells deficient in PPP2R2A display less autoimmunity and nephritis. PPP2R2A deficiency promotes NAD+ biosynthesis through the nicotinamide riboside (NR)-directed salvage pathway in T cells. NR inhibits murine Th17 and promotes Treg cell differentiation, in vitro, by PΑRylating histone H1.2 and causing its reduced occupancy in the Foxp3 loci and increased occupancy in the Il17a loci, leading to increased Foxp3 and decreased Il17a transcription. NR treatment suppresses disease in MRL.lpr mice and restores NAD+-dependent poly [ADP-ribose] polymerase 1 (PARP1) activity in CD4 T cells from patients with systemic lupus erythematosus (SLE), while reducing interferon (IFN)-γ and interleukin (IL)-17 production. We conclude that PPP2R2A controls the level of NAD+ through the NR-directed salvage pathway and promotes systemic autoimmunity. Translationally, NR suppresses lupus nephritis in mice and limits the production of proinflammatory cytokines by SLE T cells.
- Published
- 2024
- Full Text
- View/download PDF
3. CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses
- Author
-
Marc Scherlinger, Hao Li, Wenliang Pan, Wei Li, Kohei Karino, Theodoros Vichos, Afroditi Boulougoura, Nobuya Yoshida, Maria G. Tsokos, and George C. Tsokos
- Subjects
Science - Abstract
Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated B cell compartment responsible for the production of autoantibodies. Here, we show that T cell-specific expression of calcium/calmodulin-dependent protein kinase IV (CaMK4) leads to T follicular helper (Tfh) cells expansion in models of T-dependent immunization and autoimmunity. Mechanistically, CaMK4 controls the Tfh-specific transcription factor B cell lymphoma 6 (Bcl6) at the transcriptional level through the cAMP responsive element modulator α (CREMα). In the absence of CaMK4 in T cells, germinal center formation and humoral immunity is impaired in immunized mice, resulting in reduced anti-dsDNA titres, as well as IgG and complement kidney deposition in the lupus-prone B6.lpr mouse. In human Tfh cells, CaMK4 inhibition reduced BCL6 expression and IL-21 secretion ex vivo, resulting in impaired plasmablast formation and IgG production. In patients with SLE, CAMK4 mRNA levels in Tfh cells correlated with those of BCL6. In conclusion, we identify CaMK4/CREMα as a driver of T cell-dependent B cell dysregulation in autoimmunity.
- Published
- 2024
- Full Text
- View/download PDF
4. Lymphocytes in the neighborhood: good or bad for the kidney?
- Author
-
Hao Li, Maria G. Tsokos, and George C. Tsokos
- Subjects
Medicine - Abstract
Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and advances, almost invariably, to end-stage renal disease (ESRD). In this issue of the JCI, Abraham, Durkee, et al. presented a large-scale immune cell landscape of kidney biopsies from patients with LN by combining multiplexed confocal microscopy imaging with customized computer vision and quantification. The presence of diverse CD4– T cells in small neighborhoods, but not of B cells or CD4+ T cells in large neighborhoods, is linked to the development of ESRD. Unexpectedly, B cells in the kidney heralded a good prognosis. The precise location of different types of immune cells allows inference on possible interactions between different immune cells and also between immune and kidney-resident cells. The data have important implications on the development of prognostic tools and effective targeted therapies in patients with LN.
- Published
- 2022
- Full Text
- View/download PDF
5. Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells
- Author
-
Hao Li, Iannis E. Adamopoulos, Vaishali R. Moulton, Isaac E. Stillman, Zach Herbert, James J. Moon, Amir Sharabi, Suzanne Krishfield, Maria G. Tsokos, and George C. Tsokos
- Subjects
Science - Abstract
Splenic marginal zone macrophages can establish immune tolerance and limit the development of systemic lupus erythematosus (SLE). Here the authors show that these cells do this by clearing apoptotic cells, and defects in these cells result in the generation of self-reactive double negative T cells that are known to contribute to SLE pathogenesis.
- Published
- 2020
- Full Text
- View/download PDF
6. Complement and coagulation cascades in trauma
- Author
-
Abhigyan Satyam, Elizabeth R. Graef, Peter H. Lapchak, Maria G. Tsokos, Jurandir J. Dalle Lucca, and George C. Tsokos
- Subjects
Coagulation ,complement ,DAMPs ,PAMPS ,trauma ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Trauma remains a major cause of death throughout the world, especially for patients younger than 45 years. Due to rapid advances in clinical management, both in the acute and prehospital settings, trauma patients survive devastating injuries at unprecedented rates. However, these patients can often face life threatening complications that stem from the robust innate immune response induced by severe hemorrhage, leading to further tissue injury rather than repair. The complement and coagulation cascades are key mediators in this disordered reaction, which includes the development of trauma‐induced coagulopathy. There is increasing evidence that cross‐talk between these two pathways allows rapid amplification of their otherwise targeted responses and contributes to overwhelming and prolonged systemic inflammation. In this article, we summarize the initial steps of innate immune response to trauma and review the complex complement and coagulation cascades, as well as how they interact with each other. Despite progress in understanding these cascades, effective therapeutic targets have yet to be found and further research is needed both to improve survival rates as well as decrease associated morbidity.
- Published
- 2019
- Full Text
- View/download PDF
7. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis
- Author
-
Rhea Bhargava, Sylvain Lehoux, Kayaho Maeda, Maria G. Tsokos, Suzanne Krishfield, Lena Ellezian, Martin Pollak, Isaac E. Stillman, Richard D. Cummings, and George C. Tsokos
- Subjects
Autoimmunity ,Immunology ,Medicine - Abstract
Lupus nephritis (LN) is a serious complication occurring in 50% of patients with systemic lupus erythematosus (SLE) for which there is a lack of biomarkers, a lack of specific medications, and a lack of a clear understanding of its pathogenesis. The expression of calcium/calmodulin kinase IV (CaMK4) is increased in podocytes of patients with LN and lupus-prone mice, and its podocyte-targeted inhibition averts the development of nephritis in mice. Nephrin is a key podocyte molecule essential for the maintenance of the glomerular slit diaphragm. Here, we show that the presence of fucose on N-glycans of IgG induces, whereas the presence of galactose ameliorates, podocyte injury through CaMK4 expression. Mechanistically, CaMK4 phosphorylates NF-κB, upregulates the transcriptional repressor SNAIL, and limits the expression of nephrin. In addition, we demonstrate that increased expression of CaMK4 in biopsy specimens and in urine podocytes from people with LN is linked to active kidney disease. Our data shed light on the role of IgG glycosylation in the development of podocyte injury and propose the development of “liquid kidney biopsy” approaches to diagnose LN.
- Published
- 2021
- Full Text
- View/download PDF
8. PPP2R2D suppresses IL-2 production and Treg function
- Author
-
Wenliang Pan, Amir Sharabi, Andrew Ferretti, Yinfeng Zhang, Catalina Burbano, Nobuya Yoshida, Maria G. Tsokos, and George C. Tsokos
- Subjects
Autoimmunity ,Immunology ,Medicine - Abstract
Protein phosphatase 2A is a ubiquitously expressed serine/threonine phosphatase that comprises a scaffold, a catalytic, and multiple regulatory subunits and has been shown to be important in the expression of autoimmunity. We considered that a distinct subunit may account for the decreased production of IL-2 in people and mice with systemic autoimmunity. We show that the regulatory subunit PPP2R2D is increased in T cells from people with systemic lupus erythematosus and regulates IL-2 production. Mice lacking PPP2R2D only in T cells produce more IL-2 because the IL-2 gene and genes coding for IL-2–enhancing transcription factors remain open, while the levels of the enhancer phosphorylated CREB are high. Mice with T cell–specific PPP2R2D deficiency display less systemic autoimmunity when exposed to a TLR7 stimulator. While genes related to Treg function do not change in the absence of PPP2R2D, Tregs exhibit high suppressive function in vitro and in vivo. Because the ubiquitous expression of protein phosphatase 2A cannot permit systemic therapeutic manipulation, the identification of regulatory subunits able to control specific T cell functions opens the way for the development of novel, function-specific drugs.
- Published
- 2020
- Full Text
- View/download PDF
9. Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus
- Author
-
Abel Suarez-Fueyo, Maria G. Tsokos, Seung-Ki Kwok, Kayaho Maeda, Eri Katsuyama, Peter H. Lapchak, and George C. Tsokos
- Subjects
hyaluronic acid ,systemic lupus erythematosus ,extracellular matrix ,4-MU ,autoimmunity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Hyaluronic acid (HA), a component of the extracellular matrix, is the ligand for CD44 and has been implicated in the pathogenesis of kidney inflammation in patients with systemic lupus erythematosus (SLE), but its direct role and mechanism of action have not been studied. Here we show that administration of hymecromone (4-Methylumbelliferone, 4-MU), an HA synthesis inhibitor, to lupus-prone mice suppressed dramatically lupus-related pathology. Interestingly, 4-MU stopped the appearance of disease when administered prior to its onset and inhibited the progression of disease when administered after its appearance. Inhibition of HA synthesis in vivo reduced tissue damage and the number of intrarenal lymphoid cell infiltrates including double negative CD3+CD4–CD8– T cells which are known to be involved in the pathogenesis of SLE. Exposure of human peripheral blood mononuclear cells to HA in vitro increased the generation of CD3+CD4–CD8– T cells through a mechanism involving Rho-associated kinase. Our results signify the importance of the HA-rich tissue microenvironment in the activation of lymphocytes to cause tissue damage in SLE and suggest the consideration of inhibition of HA synthesis to treat patients.
- Published
- 2019
- Full Text
- View/download PDF
10. Calcium/Calmodulin Kinase IV Controls the Function of Both T Cells and Kidney Resident Cells
- Author
-
Andrew P. Ferretti, Rhea Bhargava, Shani Dahan, Maria G. Tsokos, and George C. Tsokos
- Subjects
calcium/calmodulin kinase IV ,CaMK4 ,IL-2 deprivation ,Treg deficiency ,IL-17 ,podocyte dysfunction ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Calcium calmodulin kinase IV (CaMK4) regulates multiple processes that significantly contribute to the lupus-related pathology by controlling the production of IL-2 and IL-17 by T cells, the proliferation of mesangial cells, and the function and structure of podocytes. CaMK4 is also upregulated in podocytes from patients with focal segmental glomerulosclerosis (FSGS). In both immune and non-immune podocytopathies, CaMK4 disrupts the structure and function of podocytes. In lupus-prone mice, targeted delivery of a CaMK4 inhibitor to CD4+ T cells suppresses both autoimmunity and the development of nephritis. Targeted delivery though to podocytes averts the deposition of immune complexes without affecting autoimmunity in lupus-prone mice and averts pathology induced by adriamycin in normal mice. Therefore, targeted delivery of a CaMK4 inhibitor to podocytes holds high therapeutic promise for both immune (lupus nephritis) and non-immune (FSGS) podocytopathies.
- Published
- 2018
- Full Text
- View/download PDF
11. C3a Enhances the Formation of Intestinal Organoids through C3aR1
- Author
-
Naoya Matsumoto, Abhigyan Satyam, Mayya Geha, Peter H. Lapchak, Jurandir J. Dalle Lucca, Maria G. Tsokos, and George C. Tsokos
- Subjects
complement 3 ,intestinal organoid ,intestinal stem cell ,regeneration ,ischemia/reperfusion ,Immunologic diseases. Allergy ,RC581-607 - Abstract
C3a is important in the regulation of the immune response as well as in the development of organ inflammation and injury. Furthermore, C3a contributes to liver regeneration but its role in intestinal stem cell function has not been studied. We hypothesized that C3a is important for intestinal repair and regeneration. Intestinal organoid formation, a measure of stem cell capacity, was significantly limited in C3-deficient and C3a receptor (C3aR) 1-deficient mice while C3a promoted the growth of organoids from normal mice by supporting Wnt-signaling but not from C3aR1-deficient mice. Similarly, the presence of C3a in media enhanced the expression of the intestinal stem cell marker leucine-rich repeat G-protein-coupled receptor 5 (Lgr5) and of the cell proliferation marker Ki67 in organoids formed from C3-deficient but not from C3aR1-deficient mice. Using Lgr5.egfp mice we showed significant expression of C3 in Lgr5+ intestinal stem cells whereas C3aR1 was expressed on the surface of various intestinal cells. C3 and C3aR1 expression was induced in intestinal crypts in response to ischemia/reperfusion injury. Finally, C3aR1-deficient mice displayed ischemia/reperfusion injury comparable to control mice. These data suggest that C3a through interaction with C3aR1 enhances stem cell expansion and organoid formation and as such may have a role in intestinal regeneration.
- Published
- 2017
- Full Text
- View/download PDF
12. PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma
- Author
-
Wenliang Pan, Marc Scherlinger, Nobuya Yoshida, Maria G. Tsokos, and George C. Tsokos
- Subjects
Immunology ,Immunology and Allergy - Abstract
We had shown previously that the protein phosphatase 2A regulatory subunit PPP2R2D suppresses IL-2 production, and PPP2R2D deficiency in T cells potentiates the suppressive function of regulatory T (Treg) cells and alleviates imiquimod-induced lupus-like pathology. In this study, in a melanoma xenograft model, we noted that the tumor grew in larger sizes in mice lacking PPP2R2D in T cells (LckCreR2Dfl/fl) compared with wild type (R2Dfl/fl) mice. The numbers of intratumoral T cells in LckCreR2Dfl/fl mice were reduced compared with R2Dfl/fl mice, and they expressed a PD-1+CD3+CD44+ exhaustion phenotype. In vitro experiments confirmed that the chromatin of exhaustion markers PD-1, LAG3, TIM3, and CTLA4 remained open in LckCreR2Dfl/fl CD4 T conventional compared with R2Dfl/fl T conventional cells. Moreover, the percentage of Treg cells (CD3+CD4+Foxp3+CD25hi) was significantly increased in the xenografted tumor of LckCreR2Dfl/fl mice compared with R2Dfl/fl mice probably because of the increase in the percentage of IL-2–producing LckCreR2Dfl/fl T cells. Moreover, using adoptive T cell transfer in mice xenografted with melanoma, we demonstrated that PPP2R2D deficiency in T cells enhanced the inhibitory effect of Treg cells in antitumor immunity. At the translational level, analysis of publicly available data from 418 patients with melanoma revealed that PPP2R2D expression levels correlated positively with tumor-infiltration level of CD4 and CD8 T cells. The data demonstrate that PPP2R2D is a negative regulator of immune checkpoint receptors, and its absence exacerbates effector T cell exhaustion and promotes Treg cell expansion. We conclude that PPP2R2D protects against melanoma growth, and PPP2R2D-promoting regimens can have therapeutic value in patients with melanoma.
- Published
- 2022
13. Supplemental Figure S3 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
- Author
-
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, and Adrienne H. Long
- Abstract
Increased number of MDSCs present in sarcoma tumor-bearing mice, but not in neuroblastoma tumor-bearing mice.
- Published
- 2023
14. Data from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
- Author
-
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, and Adrienne H. Long
- Abstract
Genetically engineered T cells expressing CD19-specific chimeric antigen receptors (CAR) have shown impressive activity against B-cell malignancies, and preliminary results suggest that T cells expressing a first-generation disialoganglioside (GD2)-specific CAR can also provide clinical benefit in patients with neuroblastoma. We sought to assess the potential of GD2-CAR therapies to treat pediatric sarcomas. We observed that 18 of 18 (100%) of osteosarcomas, 2 of 15 (13%) of rhabdomyosarcomas, and 7 of 35 (20%) of Ewing sarcomas expressed GD2. T cells engineered to express a third-generation GD2-CAR incorporating the 14g2a-scFv with the CD28, OX40, and CD3ζ signaling domains (14g2a.CD28.OX40.ζ) mediated efficient and comparable lysis of both GD2+ sarcoma and neuroblastoma cell lines in vitro. However, in xenograft models, GD2-CAR T cells had no antitumor effect against GD2+ sarcoma, despite effectively controlling GD2+ neuroblastoma. We observed that pediatric sarcoma xenografts, but not neuroblastoma xenografts, induced large populations of monocytic and granulocytic murine myeloid-derived suppressor cells (MDSC) that inhibited human CAR T-cell responses in vitro. Treatment of sarcoma-bearing mice with all-trans retinoic acid (ATRA) largely eradicated monocytic MDSCs and diminished the suppressive capacity of granulocytic MDSCs. Combined therapy using GD2-CAR T cells plus ATRA significantly improved antitumor efficacy against sarcoma xenografts. We conclude that retinoids provide a clinically accessible class of agents capable of diminishing the suppressive effects of MDSCs, and that co-administration of retinoids may enhance the efficacy of CAR therapies targeting solid tumors. Cancer Immunol Res; 4(10); 869–80. ©2016 AACR.
- Published
- 2023
15. Supplemental Table S1 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
- Author
-
Crystal L. Mackall, Rimas J. Orentas, Maria G. Tsokos, Susana Galli, Rana El-Etriby, Sneha Ramakrishna, Alec J. Walker, Jillian P. Smith, Yongzhi Cui, Steven L. Highfill, and Adrienne H. Long
- Abstract
GD2 expression on pediatric sarcomas
- Published
- 2023
16. Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity
- Author
-
Marc Scherlinger, Wenliang Pan, Ryo Hisada, Afroditi Boulougoura, Nobuya Yoshida, Milena Vukelic, Masataka Umeda, Suzanne Krishfield, Maria G. Tsokos, and George C. Tsokos
- Subjects
Mice ,Multidisciplinary ,Phosphofructokinases ,Animals ,Lupus Erythematosus, Systemic ,Autoimmunity ,Immunotherapy ,T-Lymphocytes, Regulatory - Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by defective regulatory T (T reg ) cells. Here, we demonstrate that a T cell–specific deletion of calcium/calmodulin-dependent protein kinase 4 (CaMK4) improves disease in B6. lpr lupus-prone mice and expands T reg cells. Mechanistically, CaMK4 phosphorylates the glycolysis rate-limiting enzyme 6-phosphofructokinase, platelet type (PFKP) and promotes aerobic glycolysis, while its end product fructose-1,6-biphosphate suppresses oxidative metabolism. In T reg cells, a CRISPR-Cas9–enabled Pfkp deletion recapitulated the metabolism of Camk4 −/− T reg cells and improved their function and stability in vitro and in vivo. In SLE CD4 + T cells, PFKP enzymatic activity correlated with SLE disease activity and pharmacologic inhibition of CaMK4-normalized PFKP activity, leading to enhanced T reg cell function. In conclusion, we provide molecular insights in the defective metabolism and function of T reg cells in SLE and identify PFKP as a target to fine-tune T reg cell metabolism and thereby restore their function.
- Published
- 2022
17. IL-27 attenuates IL-23 mediated inflammatory arthritis
- Author
-
Ritu Sarin, Ran Gu, Zahra Jalali, Emanual Maverakis, Maria G. Tsokos, and Iannis E. Adamopoulos
- Subjects
Immunology ,Immunology and Allergy - Published
- 2023
18. Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis
- Author
-
Tomohiro Koga, Masataka Umeda, Nobuya Yoshida, Abhigyan Satyam, Meenakshi Jha, Marc Scherlinger, Rhea Bhargava, Maria G Tsokos, Tomohito Sato, Kaori Furukawa, Yushiro Endo, Shoichi Fukui, Naoki Iwamoto, Norio Abiru, Minoru Okita, Masako Ito, Atsushi Kawakami, and George C Tsokos
- Subjects
Rheumatology ,Basic Science ,Pharmacology (medical) - Abstract
Objective To investigate the role of calcium/calmodulin-dependent protein kinase IV (CaMK4) in the development of joint injury in a mouse model of arthritis and patients with RA. Methods Camk4-deficient, Camk4flox/floxLck-Cre, and mice treated with CaMK4 inhibitor KN-93 or KN-93 encapsulated in nanoparticles tagged with CD4 or CD8 antibodies were subjected to collagen-induced arthritis (CIA). Inflammatory cytokine levels, humoral immune response, synovitis, and T-cell activation were recorded. CAMK4 gene expression was measured in CD4+ T cells from healthy participants and patients with active RA. Micro-CT and histology were used to assess joint pathology. CD4+ and CD14+ cells in patients with RA were subjected to Th17 or osteoclast differentiation, respectively. Results CaMK4-deficient mice subjected to CIA displayed improved clinical scores and decreased numbers of Th17 cells. KN-93 treatment significantly reduced joint destruction by decreasing the production of inflammatory cytokines. Furthermore, Camk4flox/floxLck-Cre mice and mice treated with KN93-loaded CD4 antibody-tagged nanoparticles developed fewer Th17 cells and less severe arthritis. CaMK4 inhibition mitigated IL-17 production by CD4+ cells in patients with RA. The number of in vitro differentiated osteoclasts from CD14+ cells in patients with RA was significantly decreased with CaMK4 inhibitors. Conclusion Using global and CD4-cell-targeted pharmacologic approaches and conditionally deficient mice, we demonstrate that CaMK4 is important in the development of arthritis. Using ex vivo cell cultures from patients with RA, CaMK4 is important for both Th17 generation and osteoclastogenesis. We propose that CaMK4 inhibition represents a new approach to control the development of arthritis.
- Published
- 2022
19. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy
- Author
-
Ping-Min Chen, Eri Katsuyama, Abhigyan Satyam, Hao Li, Jose Rubio, Sungwook Jung, Sylvia Andrzejewski, J. David Becherer, Maria G. Tsokos, Reza Abdi, and George C. Tsokos
- Subjects
Mice ,Multidisciplinary ,Virus Diseases ,Mitophagy ,Animals ,Humans ,Lupus Erythematosus, Systemic ,CD8-Positive T-Lymphocytes ,Mitochondria - Abstract
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD+, is up-regulated in CD8+T cells of SLE patients and correlates with the risk of infection. Here, we report that CD38 reduces CD8+T cell function by negatively affecting mitochondrial fitness through the inhibition of multiple steps of mitophagy, a process that is critical for mitochondria quality control. Using a murine lupus model, we found that administration of a CD38 inhibitor in a CD8+T cell–targeted manner reinvigorated their effector function, reversed the defects in autophagy and mitochondria, and improved viral clearance. We conclude that CD38 represents a target to mitigate infection rates in people with SLE.
- Published
- 2022
20. Intertwined pathways of complement activation command the pathogenesis of lupus nephritis
- Author
-
ABHIGYAN Satyam, RYO HISADA, RHEA BHARGAVA, MARIA G. TSOKOS, and GEORGE C. TSOKOS
- Subjects
Physiology (medical) ,Lectins ,Biochemistry (medical) ,Public Health, Environmental and Occupational Health ,Humans ,Lupus Erythematosus, Systemic ,General Medicine ,Complement System Proteins ,Complement Activation ,Lupus Nephritis ,Article - Abstract
The complement system is involved in the origin of autoimmunity and systemic lupus erythematosus. Both genetic deficiency of complement components and excessive activation are involved in primary and secondary renal diseases, including lupus nephritis. Among the pathways, the classical pathway has long been accepted as the main pathway of complement activation in systemic lupus erythematosus. However, more recent studies have shown the contribution of factors B and D which implies the involvement of the alternative pathway. While there is evidence on the role of the lectin pathway in systemic lupus erythematosus, it is yet to be demonstrated whether this pathway is protective or harmful in lupus nephritis. Complement is being explored for the development of disease biomarkers and therapeutic targeting. In the current review we discuss the involvement of complement in lupus nephritis.
- Published
- 2022
21. TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES
- Author
-
George C, Tsokos and Maria G, Tsokos
- Subjects
Benzylamines ,Mice, Inbred MRL lpr ,Sulfonamides ,Antibiotics, Antineoplastic ,Glomerulosclerosis, Focal Segmental ,T-Lymphocytes ,Membrane Proteins ,Articles ,DNA Methylation ,Lupus Nephritis ,T-Lymphocytes, Regulatory ,Disease Models, Animal ,Mice ,Drug Delivery Systems ,Doxorubicin ,CD4 Antigens ,Animals ,Humans ,Lupus Erythematosus, Systemic ,Nanoparticles ,Th17 Cells ,Molecular Targeted Therapy ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,Calcium-Calmodulin-Dependent Protein Kinase Type 4 - Abstract
We have found that calcium calmodulin kinase IV is increased in T cells, podocytes, and mesangial cells from patients with systemic lupus erythematosus, as well as in lupus-prone mice, podocytes of patients with focal segmental glomerulosclerosis, and in mice injected with doxorubicin. We showed that this accounts for aberrant T cell function and glomerular damage. Using nanoparticles (nlg) loaded with a small drug inhibitor of calcium calmodulin kinase IV and tagged with antibodies directed to CD4 we have been able to show inhibition of autoimmunity and lupus nephritis. Also, using nlg tagged with antibodies to nephrin, we showed suppression of nephritis in lupus-prone mice and of glomerular damage in mice exposed to doxorubicin. We propose the development of approaches to deliver drugs to cells in a targeted and precise manner.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.